This protocol covers ovarian endometriotic cyst presenting with endometriosis-associated pelvic pain or dysmenorrhea — a clinically significant combination that requires targeted medical management to control symptoms and limit disease progression.
Endometriosis-associated dysmenorrhea is the defining feature of this scenario. The most common symptom in younger patients is endometriosis-associated pain including dysmenorrhea, which, if mistreated, may lead to endometriosis-associated infertility.
First-line management centres on medical therapy, with a GnRH agonist as the most widely used choice — though additional hormonal options have shown comparable effectiveness. The complete protocol with the full decision framework is available via the link below.
DOI: 10.1007/s13669-011-0002-3
The most common symptom in younger patients is endometriosis-associated pain including dysmenorrhea, which, if mistreated, may lead to endometriosis-associated infertility.
A GnRH agonist is the most popular treatment choice, and a number of placebo-controlled randomized studies have shown that these are effective.
Other drugs, such as danazol, OCs, and gestrinone have also been shown to be effective, with little difference from GnRH agonists.
Dienogest, a selective progestin, was also as effective as GnRH agonists.
Rana et al. reported that a GnRH agonist or danazol is effective in reducing the size of an endometriotic cyst and in controlling pelvic pain and dysmenorrhea.
View source ↗